Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Fiche publication
Date publication
décembre 2017
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Pr KURTZ Jean-Emmanuel, Pr LANG Hervé, Dr LINDNER Véronique, Dr THIERY Alicia
Tous les auteurs :
Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz JE, Barthélémy P
Lien Pubmed
Résumé
Metastatic renal cell carcinoma (RCC) with a sarcomatoid component is a rare disease associated with a poor prognosis. We report the outcomes of 47 patients with metastatic sarcomatoid RCC (SRCC) treated with different modalities including chemotherapy, tyrosine kinase inhibitors, or immunotherapy over 2 decades in a French cancer center. Furthermore, we assessed the validity of prognostic scores in this subset of RCC.
Mots clés
Chemotherapy, Immunotherapy, Metastasis, Renal cell carcinoma, Sarcomatoid
Référence
Clin Genitourin Cancer. 2017 Dec 28;: